A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.
Epistemonikos ID: cbfda5ab14a7e4f20d8a73dfe485c55b0b35356d
First added on: Aug 29, 2025